Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to pair the device ...

The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million ...

The 12–month study involved 233 subjects, including 217 patients under the age of 18. Only 14% of the patients who received subcutaneous injections of immunoglobulin missed work or study due to ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...

The findings, published in Diabetes Technology & Therapeutics, suggest that TI could be an effective alternative for individuals seeking an option beyond multiple daily injections (MDI) or automated ...